GLP-1s Kickstart Weight Loss — But What Keeps It Off?
As the use of GLP-1 receptor agonists continues to rise across the United States, a growing body of evidence suggests that medication alone may not be sufficient to produce sustained, long-term weight loss.
A recent industry report from Weight Watchers (WW) found that individuals combining GLP-1 medications with structured lifestyle support achieved significantly greater weight loss than those using medication alone — highlighting a critical gap in how obesity is currently treated. Weight Loss Buddy (WLB), a behavioral health platform built around peer accountability and AI-driven habit reinforcement, is emerging as a scalable solution to that gap.
“The conversation is shifting from whether GLP-1 medications work to what makes them work sustainably,” said WLB Founder & CEO Joey Dweck. “Medication can reduce appetite, but it doesn’t build habits, reinforce consistency or prevent relapse. That’s where behavioral infrastructure becomes essential.”
Excerpted from Knox News
